News Dizal breaks new ground for EGFR drugs in lung cancer Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.
News Lilly's triple agonist retatrutide passes diabetes test Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.
News Generic semaglutide in India, and other weight-loss news Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.
Patients Bringing awareness to Brain Tumour Month, personally This Brain Tumour Awareness Month, Inventus' Jim Michel reveals how living with a benign brain tumour has influenced his life.
News Hope rises for vaccine against hookworm parasite Pivotal trials are being prepared for the Na-GST 1/Al–CpG vaccine, which could help address a parasite affecting hundreds of millions of people.
News Alto raises $120m for resistant depression programme Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.